The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictive model of the prognosis in non-small cell lung cancer treated with first-line immunotherapy based on machine learning.
 
Yuka Oku
No Relationships to Disclose
 
Gouji Toyokawa
No Relationships to Disclose
 
Takanori Yamashita
No Relationships to Disclose
 
Sho Wakasu
No Relationships to Disclose
 
Fumihiko Kinoshita
No Relationships to Disclose
 
Shinkichi Takamori
No Relationships to Disclose
 
Naoki Haratake
No Relationships to Disclose
 
Yoshimasa Shiraishi
Honoraria - AstraZeneca Japan
Research Funding - Chugai Pharma; Chugai Pharma
 
Mototsugu Shimokawa
No Relationships to Disclose
 
Koji Yamazaki
No Relationships to Disclose
 
Tatsuro Okamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Johnson & Johnson; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Towa Pharmaceutical
Research Funding - AnHeart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); KM Biologics (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Naoki Nakashima
No Relationships to Disclose
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tomoyoshi Takenaka
No Relationships to Disclose